Outcome (studies)
Improvement
Relative risk · 95% CI
00.511.5+
← Pacritinib
reduces riskIncreased
risk →
reduces riskIncreased
risk →
Pacritinib for COVID-19
1
study with
200
patients
Serious outcome risk
No significant improvements are seen in meta-analysis to date.
COVID-19 Pacritinib studies · November 2026
|
Outcome (studies)
Improvement
Relative risk · 95% CI
00.511.5+
← Pacritinib
reduces riskIncreased risk → |
Dec 5 2022 |
et al., JAMA Network Open, doi:10.1001/jamanetworkopen.2022.42918 | Efficacy and Safety of Pacritinib vs Placebo for Patients With Severe COVID-19 |
| 28% higher mortality (p=0.63), 25% lower progression (p=0.38), and 17% worse improvement (p=0.53). RCT 200 hospitalized patients with severe COVID-19 showing no significant differences with pacritinib. | ||
